This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should iShares S&P 500 Value ETF (IVE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVE
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is iShares Core S&P U.S. Value ETF (IUSV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IUSV
Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MGV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $163.18 in the latest trading session, marking a +0.27% move from the prior day.
Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPLV
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QUS
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
by Zacks Equity Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Johnson & Johnson (JNJ) Stock Moves -0.35%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $162.43, marking a -0.35% move from the previous day.
Amgen (AMGN) Outperforms Industry Year to Date: What's Next?
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Bristol Myers (BMY) Announces Milvexian Phase II Study Results
by Zacks Equity Research
Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
by Zacks Equity Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
by Kinjel Shah
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids
by Zacks Equity Research
AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients
J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli
by Zacks Equity Research
J&J (JNJ) gets approval for Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma. This marks the first approval for Tecvayli in any country.
These 3 Blue-Chip Stocks Are Great Shields Against Volatility
by Derek Lewis
Investing in blue-chip stocks is a stellar way to shield yourself from volatility. In addition, they generally carry hefty dividend payouts paired with a track record of excellence within their quarterly reports.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $165.58, marking a -0.33% move from the previous day.
Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYV
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
by Zacks Equity Research
Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.